## Alastair Denniston

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1364603/publications.pdf

Version: 2024-02-01

216 papers 9,068 citations

46918 47 h-index 81 g-index

227 all docs

227 docs citations

times ranked

227

8731 citing authors

#	Article	IF	CITATIONS
1	Predicting the immediate impact of national lockdown on neovascular age-related macular degeneration and associated visual morbidity: an INSIGHT Health Data Research Hub for Eye Health report. British Journal of Ophthalmology, 2023, 107, 267-274.	2.1	5
2	Metformin and risk of age-related macular degeneration in individuals with type 2 diabetes: a retrospective cohort study. British Journal of Ophthalmology, 2023, 107, 980-986.	2.1	12
3	Quantitative and qualitative assessment of anterior segment optical coherence tomography capture of disease state in childhood anterior uveitis. British Journal of Ophthalmology, 2023, 107, 966-972.	2.1	6
4	Measuring Inflammation in the Vitreous and Retina: A Narrative Review. Ocular Immunology and Inflammation, 2023, 31, 768-777.	1.0	2
5	Creating a Health Utility Value for Birdshot Chorioretinopathy. Ocular Immunology and Inflammation, 2022, 30, 73-80.	1.0	2
6	Emerging therapies and their delivery for treating ageâ€related macular degeneration. British Journal of Pharmacology, 2022, 179, 1908-1937.	2.7	23
7	Characteristics of publicly available skin cancer image datasets: a systematic review. The Lancet Digital Health, 2022, 4, e64-e74.	5.9	78
8	OCT Assisted Quantification of Vitreous Inflammation in Uveitis. Translational Vision Science and Technology, 2022, $11,3$ .	1.1	6
9	Comparison of colour contrast sensitivity in eyes at high risk of neovascular ageâ€related macular degeneration with and without subsequent choroidal neovascular membrane development. Eye, 2022, , .	1.1	O
10	Grand Challenges in global eye health: a global prioritisation process using Delphi method. The Lancet Healthy Longevity, 2022, 3, e31-e41.	2.0	19
11	Teleophthalmology-enabled and artificial intelligence-ready referral pathway for community optometry referrals of retinal disease (HERMES): a Cluster Randomised Superiority Trial with a linked Diagnostic Accuracy Study—HERMES study report 1—study protocol. BMJ Open, 2022, 12, e055845.	0.8	8
12	Consensus-based recommendations for optical coherence tomography angiography reporting in uveitis. British Journal of Ophthalmology, 2022, , bjophthalmol-2021-320021.	2.1	4
13	Clinical Evaluation of AI in Medicine. , 2022, , 645-660.		O
14	AlzEye: longitudinal record-level linkage of ophthalmic imaging and hospital admissions of 353 157 patients in London, UK. BMJ Open, 2022, 12, e058552.	0.8	22
15	The medical algorithmic audit. The Lancet Digital Health, 2022, 4, e384-e397.	5.9	85
16	Building an evidence standards framework for artificial intelligence-enabled digital health technologies. The Lancet Digital Health, 2022, 4, e216-e217.	5.9	12
17	Outreach screening to address demographic and economic barriers to diabetic retinopathy care in rural China. PLoS ONE, 2022, 17, e0266380.	1.1	2
18	Opportunities and Risks of UK Medical Device Reform. Therapeutic Innovation and Regulatory Science, 2022, 56, 596-606.	0.8	3

#	Article	IF	Citations
19	Patient reported outcome assessment must be inclusive and equitable. Nature Medicine, 2022, 28, 1120-1124.	15.2	47
20	Angiotensinâ€converting enzyme inhibitors and risk of ageâ€related macular degeneration in individuals with hypertension. British Journal of Clinical Pharmacology, 2022, , .	1.1	3
21	Therapies for Long COVID in non-hospitalised individuals: from symptoms, patient-reported outcomes and immunology to targeted therapies (The TLC Study). BMJ Open, 2022, 12, e060413.	0.8	21
22	Risk of a subsequent diagnosis of inflammatory bowel disease in subjects with ophthalmic disorders associated with inflammatory bowel disease: a retrospective cohort analysis of UK primary care data. BMJ Open, 2022, 12, e052833.	0.8	3
23	Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-Al. Nature Medicine, 2022, 28, 924-933.	15.2	125
24	Reporting guideline for the early stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-Al. BMJ, The, 2022, 377, e070904.	3.0	70
25	UK National Screening Committee's approach to reviewing evidence on artificial intelligence in breast cancer screening. The Lancet Digital Health, 2022, 4, e558-e565.	5.9	21
26	Non-invasive Instrument-Based Tests for Quantifying Anterior Chamber Flare in Uveitis: A Systematic Review. Ocular Immunology and Inflammation, 2021, 29, 982-990.	1.0	7
27	Collaborative Ocular Tuberculosis Study Consensus Guidelines on the Management of Tubercular Uveitisâ€"Report 2. Ophthalmology, 2021, 128, 277-287.	2.5	46
28	A global review of publicly available datasets for ophthalmological imaging: barriers to access, usability, and generalisability. The Lancet Digital Health, 2021, 3, e51-e66.	5.9	153
29	Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVIDâ€19. Arthritis and Rheumatology, 2021, 73, 731-739.	2.9	39
30	Advancing UK regulatory science and innovation in healthcare. Journal of the Royal Society of Medicine, 2021, 114, 5-11.	1.1	6
31	The Lancet Global Health Commission on Global Eye Health: vision beyond 2020. The Lancet Global Health, 2021, 9, e489-e551.	2.9	549
32	Collaborative Ocular Tuberculosis Study Consensus Guidelines on the Management of Tubercular Uveitisâ€"Report 1. Ophthalmology, 2021, 128, 266-276.	2.5	46
33	Advancing UK Regulatory Science Strategy in the Context of Global Regulation: a Stakeholder Survey. Therapeutic Innovation and Regulatory Science, 2021, 55, 646-655.	0.8	6
34	DECIDE-AI: new reporting guidelines to bridge the development-to-implementation gap in clinical artificial intelligence. Nature Medicine, 2021, 27, 186-187.	15,2	100
35	Automated quantification of posterior vitreous inflammation: optical coherence tomography scan number requirements. Scientific Reports, 2021, 11, 3271.	1.6	5
36	Systemic corticosteroid use in UK Uveitis practice: results from the ocular inflammation steroid toxicity risk (OSTRICH) study. Eye, 2021, 35, 3342-3349.	1.1	4

#	Article	IF	CITATIONS
37	Code-free deep learning for multi-modality medical image classification. Nature Machine Intelligence, 2021, 3, 288-298.	8.3	90
38	Health data poverty: an assailable barrier to equitable digital health care. The Lancet Digital Health, 2021, 3, e260-e265.	5.9	115
39	Predicting sex from retinal fundus photographs using automated deep learning. Scientific Reports, 2021, 11, 10286.	1.6	65
40	Reporting guidelines for artificial intelligence in healthcare research. Clinical and Experimental Ophthalmology, 2021, 49, 470-476.	1.3	26
41	Structural Endpoints and Outcome Measures in Uveitis. Ophthalmologica, 2021, 244, 465-479.	1.0	7
42	Epidemiology of Scleritis in the United Kingdom From 1997 to 2018: Populationâ€Based Analysis of 11 Million Patients and Association Between Scleritis and Infectious and Immuneâ€Mediated Inflammatory Disease. Arthritis and Rheumatology, 2021, 73, 1267-1276.	2.9	25
43	Perceptions of anonymised data use and awareness of the NHS data opt-out amongst patients, carers and healthcare staff. Research Involvement and Engagement, 2021, 7, 40.	1.1	15
44	Developing a reporting guideline for artificial intelligence-centred diagnostic test accuracy studies: the STARD-AI protocol. BMJ Open, 2021, 11, e047709.	0.8	102
45	Development and application of the ocular immune-mediated inflammatory diseases ontology enhanced with synonyms from online patient support forum conversation. Computers in Biology and Medicine, 2021, 135, 104542.	3.9	2
46	Development of a Core Outcome Set for Clinical Trials in Non-infectious Uveitis of the Posterior Segment. Ophthalmology, 2021, 128, 1209-1221.	2.5	9
47	Classification Criteria for Vogt-Koyanagi-Harada Disease. American Journal of Ophthalmology, 2021, 228, 205-211.	1.7	47
48	Stability of OCT and OCTA in the Intensive Therapy Unit Setting. Diagnostics, 2021, 11, 1516.	1.3	4
49	Review of study reporting guidelines for clinical studies using artificial intelligence in healthcare. BMJ Health and Care Informatics, 2021, 28, e100385.	1.4	35
50	Classification Criteria for Sarcoidosis-Associated Uveitis. American Journal of Ophthalmology, 2021, 228, 220-230.	1.7	39
51	Raising the Bar for Randomized Trials Involving Artificial Intelligence: The SPIRIT-Artificial Intelligence and CONSORT-Artificial Intelligence Guidelines. Journal of Investigative Dermatology, 2021, 141, 2109-2111.	0.3	15
52	Clinical Evaluation of Al in Medicine. , 2021, , 1-16.		0
53	Reporting guidelines for clinical trials of artificial intelligence interventions: the SPIRIT-AI and CONSORT-AI guidelines. Trials, 2021, 22, 11.	0.7	35
54	A quality assessment tool for artificial intelligence-centered diagnostic test accuracy studies: QUADAS-AI. Nature Medicine, 2021, 27, 1663-1665.	15.2	76

#	Article	IF	Citations
55	The Cellular Composition of the Uveal Immune Environment. Frontiers in Medicine, 2021, 8, 721953.	1.2	8
56	Standardization of Nomenclature for Ocular Tuberculosis – Results of Collaborative Ocular Tuberculosis Study (COTS) Workshop. Ocular Immunology and Inflammation, 2020, 28, 74-84.	1.0	58
57	The Uveitis Patient Passport: A Self-Care Tool. Ocular Immunology and Inflammation, 2020, 28, 433-438.	1.0	2
58	Colour contrast sensitivity in eyes at high risk of neovascular age-related macular degeneration. European Journal of Ophthalmology, 2020, 30, 1487-1494.	0.7	3
59	Objective quantification of vitreous haze on optical coherence tomography scans: no evidence for relationship between uveitis and inflammation in multiple sclerosis. European Journal of Neurology, 2020, 27, 144.	1.7	12
60	Instrument-based Tests for Measuring Anterior Chamber Cells in Uveitis: A Systematic Review. Ocular Immunology and Inflammation, 2020, 28, 898-907.	1.0	16
61	Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2020, 38, 431-441.	1.7	12
62	Comment on: â€~Quantification of anterior chamber reaction after intravitreal injections of conbercept and ranibizumab: a pilot study'. Eye, 2020, 34, 1482-1484.	1.1	0
63	Monitoring indirect impact of COVID-19 pandemic on services for cardiovascular diseases in the UK. Heart, 2020, 106, 1890-1897.	1.2	90
64	Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension. The Lancet Digital Health, 2020, 2, e549-e560.	5.9	135
65	Improving the quality of machine learning in health applications and clinical research. Nature Machine Intelligence, 2020, 2, 554-556.	8.3	45
66	Noninvasive Instrument-based Tests for Detecting and Measuring Vitreous Inflammation in Uveitis: A Systematic Review. Ocular Immunology and Inflammation, 2020, , $1-12$ .	1.0	3
67	Trends in Optic Neuritis Incidence and Prevalence in the UK and Association With Systemic and Neurologic Disease. JAMA Neurology, 2020, 77, 1514.	4.5	45
68	Outcomes important to patients with non-infectious posterior segment-involving uveitis: a qualitative study. BMJ Open Ophthalmology, 2020, 5, e000481.	0.8	11
69	Ethnicity and risk of death in patients hospitalised for COVID-19 infection in the UK: an observational cohort study in an urban catchment area. BMJ Open Respiratory Research, 2020, 7, e000644.	1.2	63
70	Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-Al extension. The Lancet Digital Health, 2020, 2, e537-e548.	5.9	112
71	Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-Al extension. Nature Medicine, 2020, 26, 1364-1374.	15.2	353
72	Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension. BMJ, The, 2020, 370, m3164.	3.0	201

#	Article	IF	Citations
73	Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension. Nature Medicine, 2020, 26, 1351-1363.	15.2	251
74	Merging Information From Infrared and Autofluorescence Fundus Images for Monitoring of Chorioretinal Atrophic Lesions. Translational Vision Science and Technology, 2020, 9, 38.	1.1	9
75	Going on up to the SPIRIT in Al: will new reporting guidelines for clinical trials of Al interventions improve their rigour?. BMC Medicine, 2020, 18, 272.	2.3	3
76	Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension. BMJ, The, 2020, 370, m3210.	3.0	157
77	The Impact of Adult Uveitis on Quality of Life: An Exploratory Study. Ophthalmic Epidemiology, 2020, 28, 1-9.	0.8	5
78	Longitudinal Development of Peripapillary Hyperâ€Reflective Ovoid Masslike Structures Suggests a Novel Pathological Pathway in <scp>Multiple Sclerosis</scp> . Annals of Neurology, 2020, 88, 309-319.	2.8	21
79	Response to Comment on "Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-Infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal― Pharmacoeconomics, 2020, 38, 649-651.	1.7	0
80	Developing specific reporting guidelines for diagnostic accuracy studies assessing Al interventions: The STARD-Al Steering Group. Nature Medicine, 2020, 26, 807-808.	15.2	166
81	Vision Loss from Atypical Optic Neuritis: Patient and Physician Perspectives. Ophthalmology and Therapy, 2020, 9, 215-220.	1.0	6
82	Insights into Systemic Disease through Retinal Imaging-Based Oculomics. Translational Vision Science and Technology, 2020, 9, 6.	1.1	103
83	A Clinician's Guide to Artificial Intelligence: How to Critically Appraise Machine Learning Studies. Translational Vision Science and Technology, 2020, 9, 7.	1.1	109
84	Adult Presentation of X-Linked Retinoschisis: Patient and Physician Perspectives. Ophthalmology and Therapy, 2020, 9, 15-19.	1.0	1
85	Triamcinolone acetonide loaded-cationic nano-lipoidal formulation for uveitis: Evidences of improved biopharmaceutical performance and anti-inflammatory activity. Colloids and Surfaces B: Biointerfaces, 2020, 190, 110902.	2.5	39
86	The Collaborative Ocular Tuberculosis Study (COTS) Consensus (CON) Group Meeting Proceedings. Ocular Immunology and Inflammation, 2020, , 1-11.	1.0	8
87	Retinal blood flow in critical illness and systemic disease: a review. Annals of Intensive Care, 2020, 10, 152.	2.2	31
88	Evaluating the Impact of Uveitis on Visual Field Progression Using Large-Scale Real-World Data. American Journal of Ophthalmology, 2019, 207, 144-150.	1.7	18
89	Automated deep learning design for medical image classification by health-care professionals with no coding experience: a feasibility study. The Lancet Digital Health, 2019, 1, e232-e242.	5.9	183
90	Extension of the CONSORT and SPIRIT statements. Lancet, The, 2019, 394, 1225.	6.3	50

#	Article	IF	CITATIONS
91	A comparison of deep learning performance against health-care professionals in detecting diseases from medical imaging: a systematic review and meta-analysis. The Lancet Digital Health, 2019, 1, e271-e297.	5.9	930
92	Reporting guidelines for clinical trials evaluating artificial intelligence interventions are needed. Nature Medicine, 2019, 25, 1467-1468.	15.2	96
93	Instrument-based tests for measuring anterior chamber cells in uveitis: a systematic review protocol. Systematic Reviews, 2019, 8, 30.	2.5	7
94	ReLayer: a Free, Online Tool for Extracting Retinal Thickness From Cross-Platform OCT Images. Translational Vision Science and Technology, 2019, 8, 25.	1.1	11
95	Patient priorities in herpes simplex keratitis. BMJ Open Ophthalmology, 2019, 4, e000177.	0.8	3
96	Under-utilisation of reproducible, child appropriate or patient reported outcome measures in childhood uveitis interventional research. Orphanet Journal of Rare Diseases, 2019, 14, 125.	1.2	11
97	Does access to a portable ophthalmoscope improve skill acquisition in direct ophthalmoscopy? A method comparison study in undergraduate medical education. BMC Medical Education, 2019, 19, 201.	1.0	3
98	The Effectiveness of Pharmacological Agents for the Treatment of Uveitic Macular Edema (UMO): A Systematic Review. Ocular Immunology and Inflammation, 2019, 27, 658-680.	1.0	6
99	Detection of Papilloedema Study (DOPS): rates of false positive papilloedema in the community. Eye, 2019, 33, 1073-1080.	1.1	13
100	<p>The use of patient-reported outcome research in modern ophthalmology: impact on clinical trials and routine clinical practice</p> . Patient Related Outcome Measures, 2019, Volume 10, 9-24.	0.7	86
101	Adalimumab for non-infectious uveitis: is it cost-effective?. British Journal of Ophthalmology, 2019, 103, 1633-1638.	2.1	5
102	Comprehensive sequencing of the myocilin gene in a selected cohort of severe primary open-angle glaucoma patients. Scientific Reports, 2019, 9, 3100.	1.6	8
103	Dexamethasone implant for non-infectious uveitis: is it cost-effective?. British Journal of Ophthalmology, 2019, 103, 1639-1644.	2.1	4
104	Instrument-based tests for quantifying aqueous humour protein levels in uveitis: a systematic review protocol. Systematic Reviews, 2019, 8, 287.	2.5	4
105	Optical coherence tomography (OCT) in unconscious and systemically unwell patients using a mobile OCT device: a pilot study. BMJ Open, 2019, 9, e030882.	0.8	20
106	United Kingdom Diabetic Retinopathy Electronic Medical Record (UK DR EMR) Users Group: report 4, real-world data on the impact of deprivation on the presentation of diabetic eye disease at hospital services. British Journal of Ophthalmology, 2019, 103, 837-843.	2.1	25
107	Time to regenerate: the doctor in the age of artificial intelligence. Journal of the Royal Society of Medicine, 2018, 111, 113-116.	1.1	22
108	Optimizing OCT acquisition parameters for assessments of vitreous haze for application in uveitis. Scientific Reports, 2018, 8, 1648.	1.6	24

#	Article	IF	CITATIONS
109	Characteristic optical coherence tomography findings in patients with primary vitreoretinal lymphoma: a novel aid to early diagnosis. British Journal of Ophthalmology, 2018, 102, 1362-1366.	2.1	70
110	Clinical efficacy and safety of a light mask for prevention of dark adaptation in treating and preventing progression of early diabetic macular oedema at 24 months (CLEOPATRA): a multicentre, phase 3, randomised controlled trial. Lancet Diabetes and Endocrinology, the, 2018, 6, 382-391.	5.5	25
111	False Negative Toxoplasma Serology in an Immunocompromised Patient with PCR Positive Ocular Toxoplasmosis. Ocular Immunology and Inflammation, 2018, 26, 1200-1202.	1.0	13
112	An overview of the clinical applications of optical coherence tomography angiography. Eye, 2018, 32, 262-286.	1.1	152
113	Multiple deprivation, vision loss, and ophthalmic disease in adults: global perspectives. Survey of Ophthalmology, 2018, 63, 406-436.	1.7	30
114	Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis. The Cochrane Library, 2018, 2018, CD012577.	1.5	7
115	Iluvienâ,,¢ (Fluocinolone Acetonide 0.19Âmg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review. Ophthalmology and Therapy, 2018, 7, 293-305.	1.0	23
116	mTOR-inhibiting pharmacotherapy for the treatment of non-infectious uveitis: a systematic review protocol. Systematic Reviews, 2018, 7, 83.	2.5	3
117	Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvienâ,,¢) at 2 years. BMC Ophthalmology, 2018, 18, 62.	0.6	42
118	The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, Report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema. British Journal of Ophthalmology, 2017, 101, 75-80.	2.1	57
119	Quantitative analysis of vitreous inflammation using optical coherence tomography in patients receiving sub-Tenon's triamcinolone acetonide for uveitic cystoid macular oedema. British Journal of Ophthalmology, 2017, 101, 175-179.	2.1	23
120	Cataract surgery in uveitis: a multicentre database study. British Journal of Ophthalmology, 2017, 101, 1132-1137.	2.1	48
121	"The patient is speaking― discovering the patient voice in ophthalmology. British Journal of Ophthalmology, 2017, 101, 700-708.	2.1	71
122	The UK Diabetic Retinopathy Electronic Medical Record (UK DR EMR) Users Group, Report 2: real-world data for the impact of cataract surgery on diabetic macular oedema. British Journal of Ophthalmology, 2017, 101, 1673-1678.	2.1	65
123	The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group: Report 3: Baseline Retinopathy and Clinical Features Predict Progression of Diabetic Retinopathy. American Journal of Ophthalmology, 2017, 180, 64-71.	1.7	34
124	Uveitis: a sight-threatening disease which can impact all systems. Postgraduate Medical Journal, 2017, 93, 766-773.	0.9	79
125	Birdshot Chorioretinopathy. Ocular Immunology and Inflammation, 2017, 25, 589-593.	1.0	9
126	Birmingham Behçet's service: classification of disease and application of the 2014 International Criteria for Behçet's Disease (ICBD) to a UK cohort. BMC Musculoskeletal Disorders, 2017, 18, 101.	0.8	15

#	Article	IF	Citations
127	The use of transdermal optical coherence tomography to image the superficial temporal arteries. Eye, 2017, 31, 157-160.	1.1	8
128	Punctate inner choroidopathy: A review. Survey of Ophthalmology, 2017, 62, 113-126.	1.7	72
129	Development and validation of a questionnaire assessing the quality of life impact of Colour Blindness (CBQoL). BMC Ophthalmology, 2017, 17, 179.	0.6	19
130	Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis. The Cochrane Library, $2017$ , , .	1.5	3
131	A retrospective cohort study of patients treated with anti-tuberculous therapy for presumed ocular tuberculosis. Journal of Ophthalmic Inflammation and Infection, 2017, 7, 23.	1.2	14
132	Tubulointerstitial nephritis and uveitis (TINU) syndrome: a systematic review of its epidemiology, demographics and risk factors. Orphanet Journal of Rare Diseases, 2017, 12, 128.	1.2	53
133	An update on the use of biologic therapies in the management of uveitis in Behçet's disease: a comprehensive review. Orphanet Journal of Rare Diseases, 2017, 12, 130.	1.2	21
134	COSUMO: study protocol for the development of a core outcome set for efficacy and effectiveness trials in posterior segment-involving uveitis. Trials, 2017, 18, 576.	0.7	12
135	Biomarkers and Surrogate Endpoints in Uveitis: The Impact of Quantitative Imaging., 2017, 58, BIO131.		46
136	The Ocular Glymphatic System and Idiopathic Intracranial Hypertension: Author Response to "Hypodense Holes and the Ocular Glymphatic System―, 2017, 58, 1134.		14
137	Patent foramen ovale presenting as visual loss. JRSM Open, 2017, 8, 205427041666930.	0.2	6
138	A Comprehensive Review of mTOR-Inhibiting Pharmacotherapy for the Treatment of Non-Infectious Uveitis. Current Pharmaceutical Design, 2017, 23, 3005-3014.	0.9	14
139	A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults. Health Technology Assessment, 2017, 21, 1-170.	1.3	26
140	Visualizing the Choriocapillaris Under Drusen: Comparing 1050-nm Swept-Source Versus 840-nm Spectral-Domain Optical Coherence Tomography Angiography. , 2016, 57, OCT585.		95
141	Conjunctival Neutrophils Predict Progressive Scarring in Ocular Mucous Membrane Pemphigoid. , 2016, 57, 5457.		23
142	"Black Holes―and the Ocular Glymphatic System: Author Response to "The Glymphatic System: A New Player in Ocular Diseases?― , 2016, 57, 5428.		2
143	Correspondence. Retina, 2016, 36, e1.	1.0	0
144	Birdshot chorioretinopathy: current knowledge and new concepts in pathophysiology, diagnosis, monitoring and treatment. Orphanet Journal of Rare Diseases, 2016, 11, 61.	1,2	92

#	Article	IF	Citations
145	VISUALising a new framework for the treatment of uveitis. Lancet, The, 2016, 388, 1134-1136.	6.3	4
146	Adjunctive use of systematic retinal thickness map analysis to monitor disease activity in punctate inner choroidopathy. Journal of Ophthalmic Inflammation and Infection, 2016, 6, 9.	1.2	8
147	The effectiveness of pharmacological agents for the treatment of uveitic macular oedema (UMO): a systematic review protocol. Systematic Reviews, 2016, 5, 29.	2.5	10
148	Previous Intravitreal Therapy Is Associated with Increased Risk of Posterior Capsule Rupture during Cataract Surgery. Ophthalmology, 2016, 123, 1252-1256.	2.5	39
149	Drug discovery in ophthalmology: past success, present challenges, and future opportunities. BMC Ophthalmology, 2016, 16, 11.	0.6	34
150	Evaluation of Objective Vitritis Grading Method Using Optical Coherence Tomography: Influence of Phakic Status and Previous Vitrectomy. American Journal of Ophthalmology, 2016, 161, 172-180.e4.	1.7	31
151	Hydroxychloroquine-related retinal toxicity. Rheumatology, 2016, 55, 957-967.	0.9	77
152	Systemic lupus erythematosus: An update for ophthalmologists. Survey of Ophthalmology, 2016, 61, 65-82.	1.7	29
153	Heterogeneity of primary outcome measures used in clinical trials of treatments for intermediate, posterior, and panuveitis. Orphanet Journal of Rare Diseases, 2015, 10, 97.	1.2	48
154	Social deprivation as a risk factor for late presentation of proliferative diabetic retinopathy. Clinical Ophthalmology, 2015, 9, 347.	0.9	24
155	Paravascular Pathways in the Eye: Is There an †Ocular Glymphatic System'?. , 2015, 56, 3955.		45
156	Automated Analysis of Vitreous Inflammation Using Spectral-Domain Optical Coherence Tomography. Translational Vision Science and Technology, 2015, 4, 4.	1.1	36
157	Role of dendritic cell subsets in immunity and their contribution to noninfectious uveitis. Survey of Ophthalmology, 2015, 60, 242-249.	1.7	26
158	Increased CD1c+ mDC1 with mature phenotype regulated by TNFα–p38 MAPK in autoimmune ocular inflammatory disease. Clinical Immunology, 2015, 158, 35-46.	1.4	8
159	Increase in admissions related to giant cell arteritis and polymyalgia rheumatica in the UK, 2002-13, without a decrease in associated sight loss: potential implications for service provision. Rheumatology, 2015, 54, 375-377.	0.9	15
160	AUTOIMMUNE RETINOPATHY – IMPORTANCE OF RECOVERIN B ANTIBODIES. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.180-e4.	0.9	0
161	Controversies in the Pharmacological Treatment of Uveitis. Current Pharmaceutical Design, 2015, 21, 4682-4687.	0.9	17
162	Pharmacotherapy for uveitis: current management and emerging therapy. Clinical Ophthalmology, 2014, 8, 1891.	0.9	53

#	Article	IF	Citations
163	Lowering the limit: reducing the CD4 T-cell threshold for ophthalmic screening in patients with HIV in an ethnically diverse UK population. Clinical Ophthalmology, 2014, 8, 2029.	0.9	1
164	An introduction to patient-reported outcome measures in ophthalmic research. Eye, 2014, 28, 637-645.	1.1	50
165	The role of social deprivation in severe neovascular age-related macular degeneration: TableÂ1. British Journal of Ophthalmology, 2014, 98, 1625-1628.	2.1	17
166	Patient Information in Graves' Disease and Thyroid-Associated Ophthalmopathy: Readability Assessment of Online Resources. Thyroid, 2014, 24, 67-72.	2.4	41
167	EVALUATION OF VISUAL FUNCTION AND NEEDS IN ADULT PATIENTS WITH BARDET–BIEDL SYNDROME. Retina, 2014, 34, 2282-2289.	1.0	25
168	Evidence-based practice in Behçet's disease: identifying areas of unmet need for 2014. Orphanet Journal of Rare Diseases, 2014, 9, 16.	1.2	13
169	Detection of branch retinal artery occlusions in Susac's syndrome. BMC Research Notes, 2014, 7, 56.	0.6	7
170	Aspirin as adjunctive treatment for giant cell arteritis. The Cochrane Library, 2014, , CD010453.	1.5	26
171	Objective Measurement of Vitreous Inflammation Using Optical Coherence Tomography. Ophthalmology, 2014, 121, 1706-1714.	2.5	104
172	Long-term biocompatibility and visual outcomes of a hydrophilic acrylic intraocular lens in patients with uveitis. Journal of Cataract and Refractive Surgery, 2014, 40, 618-625.	0.7	16
173	Development and Validation of Quality-of-Life Questionnaires for Birdshot Chorioretinopathy. Ophthalmology, 2014, 121, 1488-1489.e2.	2.5	13
174	Systemic therapies for inflammatory eye disease: Past, Present and Future. BMC Ophthalmology, 2013, 13, 18.	0.6	25
175	Rheumatic Disease. , 2013, , 1415-1440.		O
176	Elevation of Conjunctival Epithelial CD45 <sup>H</sup> CD16 <sup>H</sup> CD14 <sup>A^'</sup> Neutrophils in Ocular Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis., 2013, 54, 4578.		22
177	Ten-year experience of pulsed intravenous cyclophosphamide and methylprednisolone protocol (PICM) Tj ETQq $1\ 1$	0.784314 2:1	1 <sub>2</sub> gBT /Ove
178	Characterization of Birdshot Chorioretinopathy Using Extramacular Enhanced Depth Optical Coherence Tomography. JAMA Ophthalmology, 2013, 131, 341.	1.4	98
179	When You Can Have the Bird Without Shooting It!: Extramacular Enhanced Depth Optical Coherence Tomography in Birdshot Chorioretinopathy—Reply. JAMA Ophthalmology, 2013, 131, 1369.	1.4	1
180	Readability Assessment of Online Ophthalmic Patient Information. JAMA Ophthalmology, 2013, 131, 1610.	1.4	95

#	Article	IF	CITATIONS
181	Measurement bias between optical coherence tomography instruments can affect access to treatment: a new lottery. Clinical Ophthalmology, 2013, 7, 2299.	0.9	1
182	Childhood blepharokeratoconjunctivitis: characterising a severe phenotype in white adolescents. British Journal of Ophthalmology, 2012, 96, 949-955.	2.1	23
183	Diagnostic and Therapeutic Challenges. Retina, 2012, 32, 197-202.	1.0	1
184	The dominant human conjunctival epithelial CD8 $\hat{i}$ ± $\hat{i}$ 2+ T cell population is maintained with age but the number of CD4+ T cells increases. Age, 2012, 34, 1517-1528.	3.0	20
185	Aqueous Humor Suppression of Dendritic Cell Function Helps Maintain Immune Regulation in the Eye during Human Uveitis., 2012, 53, 888.		27
186	Intraocular Immune Mechanisms in Uveitis. Current Immunology Reviews, 2011, 7, 350-359.	1.2	2
187	Safety profile of anterior chamber paracentesis performed at the slit lamp. Clinical and Experimental Ophthalmology, 2011, 39, 725-728.	1.3	59
188	Rheumatoid corneal melt: autoimmunity or infection?. JRSM Short Reports, 2011, 2, 1-4.	0.6	36
189	Endogenous Cortisol and TGF- $\hat{l}^2$ in Human Aqueous Humor Contribute to Ocular Immune Privilege by Regulating Dendritic Cell Function. Journal of Immunology, 2011, 186, 305-311.	0.4	34
190	Survey of Expert Practice and Perceptions of the Supporting Clinical Evidence for the Management of Uveitis-related Cataract and Cystoid Macular Oedema. Ocular Immunology and Inflammation, 2011, 19, 353-357.	1.0	19
191	Comparison of two ophthalmoscopes for direct ophthalmoscopy. Clinical and Experimental Ophthalmology, 2010, 39, no-no.	1.3	8
192	Reply to Wertheim et al. Eye, 2010, 24, 1116-1116.	1.1	0
193	Distinct Types of Fibrocyte Can Differentiate from Mononuclear Cells in the Presence and Absence of Serum. PLoS ONE, 2010, 5, e9730.	1.1	49
194	Research into Glaucoma And Ethnicity (ReGAE) 8: is there a relationship between social deprivation and acute primary angle closure?. British Journal of Ophthalmology, 2010, 94, 1304-1306.	2.1	22
195	Bilateral retinal vasculitis in a patient with systemic lupus erythematosus and its remission with rituximab therapy. Lupus, 2010, 19, 327-329.	0.8	36
196	Is ethnicity a risk factor for severe retinopathy of prematurity?. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2010, 95, F174-F176.	1.4	50
197	Phacoemulsification and foldable intraocular lens implantation combined with 23-gauge transconjunctival sutureless vitrectomy. Journal of Cataract and Refractive Surgery, 2009, 35, 1380-1384.	0.7	41
198	What Can the Aqueous Humour Tell Us About Uveitis?. Essentials in Ophthalmology, 2009, , 19-27.	0.0	2

#	Article	IF	CITATIONS
199	Soluble gp130, an Antagonist of IL-6 Transsignaling, Is Elevated in Uveitis Aqueous Humor., 2008, 49, 3988.		20
200	Ocular manifestations of systemic lupus erythematosus. Rheumatology, 2007, 46, 1757-1762.	0.9	184
201	Cardiovascular therapies and their role in diabetic eye disease. Diabetic Medicine, 2005, 22, 665-666.	1.2	4
202	More on porphyrias. Lancet, The, 2005, 365, 937.	6.3	2
203	Oral valganciclovir treatment of varicella zoster virus acute retinal necrosis. Eye, 2004, 18, 544-545.	1.1	32
204	Ophthalmic features of Turner's syndrome. Eye, 2004, 18, 680-684.	1.1	45
205	Does cardiovascular therapy affect the onset and recurrence of preretinal and vitreous haemorrhage in diabetic eye disease?. Eye, 2004, 18, 821-825.	1.1	14
206	Dancing eyes. British Journal of Hospital Medicine, 2003, 64, 555-556.	0.3	0
207	The use of oxygen in acute exacerbations of chronic obstructive pulmonary disease: a prospective audit of pre-hospital and hospital emergency management. Clinical Medicine, 2002, 2, 449-451.	0.8	62
208	Diagnosis and management of thyroid eye disease. British Journal of Hospital Medicine, 2002, 63, 152-156.	0.3	6
209	Turner's syndrome. Lancet, The, 2001, 358, 2169-2170.	6.3	3
210	Carbon Monoxide Poisoning and the Eye. Journal of the Royal Society of Medicine, 2001, 94, 425-426.	1.1	3
211	The use of botulinum toxin in ophthalmology. British Journal of Hospital Medicine, 2001, 62, 477-479.	0.3	5
212	Deep Learning Under Scrutiny: Performance Against Health Care Professionals in Detecting Diseases from Medical Imaging - Systematic Review and Meta-Analysis. SSRN Electronic Journal, 0, , .	0.4	5
213	Ethnicity and Risk of Death in Patients Hospitalised for COVID-19 Infection: An Observational Cohort Study in an Urban Catchment Area. SSRN Electronic Journal, 0, , .	0.4	2
214	Development and External Validation of Prognostic Models for COVID-19 to Support Risk Stratification in Secondary Care. SSRN Electronic Journal, 0, , .	0.4	0
215	Outreach Screening to Address Demographic and Economic Barriers to Diabetic Retinopathy Care in Rural China. SSRN Electronic Journal, 0, , .	0.4	0
216	Development of a Nationally Agreed Core Clinical Dataset for Childhood Onset Uveitis. Frontiers in Pediatrics, 0, 10, .	0.9	3